Goldman Sachs Initiates Coverage On Stoke Therapeutics with Buy Rating, Announces Price Target of $44

Goldman Sachs analyst Kevin Strang initiates coverage on Stoke Therapeutics (NASDAQ:STOK) with a Buy rating and announces Price Target of $44.